In Vitro Study on Synergistic Interactions Between Free and Encapsulated Q-Griffithsin and Antiretrovirals Against HIV-1 Infection

Overview

Journal Int J Nanomedicine

Publisher Dove Medical Press

Specialty Biotechnology

Date 2021 Feb 24

PMID 33623382

Citations 4

Authors

Farnaz Minooei

Joel R Fried

Joshua L Fuqua

Kenneth E Palmer

Jill M Steinbach-Rankins

Affiliations

Soon will be listed here.

Abstract

Introduction: Human immunodeﬁciency virus (HIV) remains a persistent global challenge, impacting 38 million people worldwide. Antiretrovirals (ARVs) including tenofovir (TFV), raltegravir (RAL), and dapivirine (DAP) have been developed to prevent and treat HIV-1 via different mechanisms of action. In parallel, a promising biological candidate, griffithsin (GRFT), has demonstrated outstanding preclinical safety and potency against HIV-1. While ARV co-administration has been shown to enhance virus inhibition, synergistic interactions between ARVs and the oxidation-resistant variant of GRFT (Q-GRFT) have not yet been explored. Here, we co-administered Q-GRFT with TFV, RAL, and DAP, in free and encapsulated forms, to identify unique protein-drug synergies.

Methods: Nanoparticles (NPs) were synthesized using a single or double-emulsion technique and release from each formulation was assessed in simulated vaginal fluid. Next, each ARV, in free and encapsulated forms, was co-administered with Q-GRFT or Q-GRFT NPs to evaluate the impact of co-administration in HIV-1 pseudovirus assays, and the combination indices were calculated to identify synergistic interactions. Using the most synergistic formulations, we investigated the effect of agent incorporation in NP-fiber composites on release properties. Finally, NP safety was assessed in vitro using MTT assay.

Results: All active agents were encapsulated in NPs with desirable encapsulation efficiency (15-100%), providing ~20% release over 2 weeks. The co-administration of free Q-GRFT with each free ARV resulted in strong synergistic interactions, relative to each agent alone. Similarly, Q-GRFT NP and ARV NP co-administration resulted in synergy across all formulations, with the most potent interactions between encapsulated Q-GRFT and DAP. Furthermore, the incorporation of Q-GRFT and DAP in NP-fiber composites resulted in burst release of DAP and Q-GRFT with a second phase of Q-GRFT release. Finally, all NP formulations exhibited safety in vitro.

Conclusions: This work suggests that Q-GRFT and ARV co-administration in free or encapsulated forms may improve efficacy in achieving prophylaxis.

Citing Articles

Sustained Delivery of the Antiviral Protein Griffithsin and Its Adhesion to a Biological Surface by a Silk Fibroin Scaffold.

Guan W, Zhang N, Bains A, Martinez A, LiWang P Materials (Basel). 2023; 16(16).

PMID: 37629837 PMC: 10456748. DOI: 10.3390/ma16165547.

The Advances of Broad-Spectrum and Hot Anti-Coronavirus Drugs.

Zeng S, Li Y, Zhu W, Luo Z, Wu K, Li X Microorganisms. 2022; 10(7).

PMID: 35889013 PMC: 9317368. DOI: 10.3390/microorganisms10071294.

Comprehensive analysis of lectin-glycan interactions reveals determinants of lectin specificity.

Mattox D, Bailey-Kellogg C PLoS Comput Biol. 2021; 17(10):e1009470.

PMID: 34613971 PMC: 8523061. DOI: 10.1371/journal.pcbi.1009470.

Natural Products with Inhibitory Activity against Human Immunodeficiency Virus Type 1.

Serna-Arbelaez M, Florez-Sampedro L, Orozco L, Ramirez K, Galeano E, Zapata W Adv Virol. 2021; 2021:5552088.

PMID: 34194504 PMC: 8181102. DOI: 10.1155/2021/5552088.

References

Cohen M, Chen Y, McCauley M, Gamble T, Hosseinipour M, Kumarasamy N . Antiretroviral Therapy for the Prevention of HIV-1 Transmission. N Engl J Med. 2016; 375(9):830-9. PMC: 5049503. DOI: 10.1056/NEJMoa1600693. View

Baeten J, Palanee-Phillips T, Brown E, Schwartz K, Soto-Torres L, Govender V . Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women. N Engl J Med. 2016; 375(22):2121-2132. PMC: 4993693. DOI: 10.1056/NEJMoa1506110. View

Guthrie K, Vargas S, Shaw J, Rosen R, Berg J, Kiser P . The Promise of Intravaginal Rings for Prevention: User Perceptions of Biomechanical Properties and Implications for Prevention Product Development. PLoS One. 2015; 10(12):e0145642. PMC: 4690611. DOI: 10.1371/journal.pone.0145642. View

Ensign L, Tang B, Wang Y, Tse T, Hoen T, Cone R . Mucus-penetrating nanoparticles for vaginal drug delivery protect against herpes simplex virus. Sci Transl Med. 2012; 4(138):138ra79. PMC: 3817739. DOI: 10.1126/scitranslmed.3003453. View

Mori T, OKeefe B, Sowder 2nd R, Bringans S, Gardella R, Berg S . Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp. J Biol Chem. 2004; 280(10):9345-53. DOI: 10.1074/jbc.M411122200. View

Budhian A, Siegel S, Winey K . Haloperidol-loaded PLGA nanoparticles: systematic study of particle size and drug content. Int J Pharm. 2007; 336(2):367-75. DOI: 10.1016/j.ijpharm.2006.11.061. View

Blakney A, Krogstad E, Jiang Y, Woodrow K . Delivery of multipurpose prevention drug combinations from electrospun nanofibers using composite microarchitectures. Int J Nanomedicine. 2014; 9:2967-78. PMC: 4069153. DOI: 10.2147/IJN.S61664. View

Machado A, Cunha-Reis C, Araujo F, Nunes R, Seabra V, Ferreira D . Development and in vivo safety assessment of tenofovir-loaded nanoparticles-in-film as a novel vaginal microbicide delivery system. Acta Biomater. 2016; 44:332-40. DOI: 10.1016/j.actbio.2016.08.018. View

Thigpen M, Kebaabetswe P, Paxton L, Smith D, Rose C, Segolodi T . Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012; 367(5):423-34. DOI: 10.1056/NEJMoa1110711. View

10.

Mallipeddi R, Rohan L . Nanoparticle-based vaginal drug delivery systems for HIV prevention. Expert Opin Drug Deliv. 2009; 7(1):37-48. DOI: 10.1517/17425240903338055. View

11.

Corman J, Hamorsky K, Shepherd J, Hiatt E, Fuqua J, Palmer K . Stability of plasmid and viral banks supporting the cGMP manufacture of Q-Griffithsin from a TMV-based viral vector. J Biotechnol. 2020; 320:74-76. PMC: 7397727. DOI: 10.1016/j.jbiotec.2020.06.009. View

12.

Steinbach J, Seo Y, Saltzman W . Cell penetrating peptide-modified poly(lactic-co-glycolic acid) nanoparticles with enhanced cell internalization. Acta Biomater. 2015; 30:49-61. PMC: 4695306. DOI: 10.1016/j.actbio.2015.11.029. View

13.

Panyam J, Labhasetwar V . Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev. 2003; 55(3):329-47. DOI: 10.1016/s0169-409x(02)00228-4. View

14.

Barton C, Kouokam J, Lasnik A, Foreman O, Cambon A, Brock G . Activity of and effect of subcutaneous treatment with the broad-spectrum antiviral lectin griffithsin in two laboratory rodent models. Antimicrob Agents Chemother. 2013; 58(1):120-7. PMC: 3910741. DOI: 10.1128/AAC.01407-13. View

15.

Jiang Y, Cao S, Bright D, Bever A, Blakney A, Suydam I . Nanoparticle-Based ARV Drug Combinations for Synergistic Inhibition of Cell-Free and Cell-Cell HIV Transmission. Mol Pharm. 2015; 12(12):4363-74. DOI: 10.1021/acs.molpharmaceut.5b00544. View

16.

Marrazzo J, Ramjee G, Richardson B, Gomez K, Mgodi N, Nair G . Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015; 372(6):509-18. PMC: 4341965. DOI: 10.1056/NEJMoa1402269. View

17.

OKeefe B, Giomarelli B, Barnard D, Shenoy S, Chan P, McMahon J . Broad-spectrum in vitro activity and in vivo efficacy of the antiviral protein griffithsin against emerging viruses of the family Coronaviridae. J Virol. 2009; 84(5):2511-21. PMC: 2820936. DOI: 10.1128/JVI.02322-09. View

18.

Richman D, Fischl M, GRIECO M, Gottlieb M, Volberding P, Laskin O . The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987; 317(4):192-7. DOI: 10.1056/NEJM198707233170402. View

19.

Grooms T, Vuong H, Tyo K, Malik D, Sims L, Whittington C . Griffithsin-Modified Electrospun Fibers as a Delivery Scaffold To Prevent HIV Infection. Antimicrob Agents Chemother. 2016; 60(11):6518-6531. PMC: 5075055. DOI: 10.1128/AAC.00956-16. View

20.

Blakney A, Ball C, Krogstad E, Woodrow K . Electrospun fibers for vaginal anti-HIV drug delivery. Antiviral Res. 2013; 100 Suppl:S9-16. DOI: 10.1016/j.antiviral.2013.09.022. View